A substantial and growing body of evidence supports the efficacy and safety of Meniett therapy, such as:

• A long-term case study by Rajan et al. showed that participants' vertigo, functionality, and hearing levels all improved while using the Meniett device.¹ Learn more.

• Thomsen et al. demonstrated that patients who used Meniett therapy experienced significantly increased functionality² in their lives and a significant reduction in vertigo severity.³ Learn more.

• Gates et al. found that patients who used the Meniett experienced significantly less severe vertigo, fewer days with vertigo, and fewer days missed from work due to the disease.⁴ Learn more.

• In a two-year follow-up, Densert et al. showed that Meniett therapy significantly improved vertigo symptoms and functionality in 92 percent of patients.⁵ Learn more.

For additional references, click here.

2005. In this long-term case study by Rajan et al., patients had their vertigo, functionality and hearing levels assessed before beginning Meniett therapy. They were evaluated again six months, 12 months, and 18 months later. For 67 percent of participants, there was significant, long-term improvement in vertigo symptoms and functionality. Twenty-seven percent also showed significant improvement in hearing. All of the patients with no improvement had undergone previous surgical or chemical treatment for the disease.¹

"According to this independent study, the Meniett device seems to be a minimally invasive, non-destructive treatment tool, which can reduce vertigo and associated functional handicap in Ménière's Disease. These effects are maintained up to 18 months after treatment so far," writes Gunesh Rajan, MD, principal investigator of the study and professor of otolaryngology-head and neck surgery at the Lions Ear and Hearing Institute – Sir Charles Gairdner Hospital, University of Western Australia in Australia.

Back to top

2005. Forty people with established Ménière's Disease unresponsive to medical therapy were evaluated for four months in this randomized, placebo-controlled, double-blind, multicenter study by Thomsen et al. Patients who used the Meniett therapy experienced significantly increased functionality in their lives as measured using AAO-HNS criteria² and a significant reduction in vertigo intensity compared to patients in the control group.³

Functionality level is an important indicator of a Ménière's Disease patient's quality of life and how well disease symptoms are being managed. The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) created a self-assessed, six-point functional level scale to help determine the effects of vertigo symptoms on daily activities. Click here for an image of the scale. 

click on image to view larger

"Local overpressure treatment is…non-destructive and safe. It reduces hydrops [the excess inner ear fluid that causes disease symptoms] and can be repeated as many times as needed," writes Jens Thomsen, MD, principal investigator of the study and professor of otolaryngology-head and neck surgery at Gentofte University Hospital in Denmark.

Back to top

2004. Results of a US clinical study reported that patients who used the Meniett device for Ménière's Disease experienced significantly less severe vertigo, fewer days with vertigo, and fewer days missed from work due to the disease compared to patients in the control group. The randomized, placebo-controlled, double-blind, multicenter trial by Gates et al. evaluated 62 people for four months. Each had established Ménière's Disease that was unresponsive to medical therapy. There were no complications from the device.⁴

"We recommend that patients, physicians and healthcare insurers recognize the Meniett device as a second-level therapy for Ménière's Disease [after medical therapy fails and before surgical or destructive treatment is considered]," writes George Gates, MD, principal investigator of the US Meniett Clinical Study and professor emeritus of otolaryngology and director of the Virginia Merrill Bloedel Research Center, University of Washington Medical Center.

Back to top

2001. This two-year follow-up study by Densert et al. involved 37 Ménière's Disease patients. Thirty-one of the 37 patients had failed medical treatment prior to enrollment. Study results showed that the Meniett treatment significantly improved vertigo symptoms and functionality levels in 92 percent of patients. No side effects related to the treatment were reported.⁵

1. Rajan, G.P., S. Din, and M.D. Atlas. 2005. Long-term effects of the Meniett device in Ménière's Disease: the Western Australian experience. J Laryngol Otol 119:391-395.
2. Monsell, E.M. 1995. American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Ménière's Disease. Otolaryngology - Head and Neck Surgery 113(3): 176-8.
3. Thomsen, J., K. Sass, L. Ödkvist, and S. Arlinger. 2005. Local over-pressure treatment reduces vestibular symptoms in patients with Ménière's Disease: a clinical, randomized, multicenter, double-blind, placebo-controlled study. Otol Neurotol 26:68-73.
4. Gates G.A., J.D. Green, Jr., D.L. Tucci, and S.A. Telian. 2004. The effects of transtympanic micropressure treatment in people with unilateral Ménière's Disease. Arch of Oto - HNS, June:130(6): 718-725. 
5. Densert, B., and K. Sass. 2001. Control of symptoms in patients with Ménière's Disease using middle ear applications: A two-year follow-up. Acta Otolaryngol (Stockh) 120:5.

Back to top